Feng G, Valenti L, Wong V, Fouad Y, Yilmaz Y, Kim W, et al. Recompensation in cirrhosis: unraveling the evolving natural history of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2024;21:46–56

Article  PubMed  Google Scholar 

Younossi ZM. Non-alcoholic fatty liver disease—a global public health perspective. J Hepatol. 2019;70:531–544

Article  PubMed  Google Scholar 

Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019;71:793–801

Article  PubMed  Google Scholar 

Singh S, Allen A, Wang Z, Prokop L, Murad M, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015;13:643–654

Article  PubMed  Google Scholar 

Ampuero J, Aller R, Gallego-Duran R, Banales JM, Crespo J, Garcia-Monzon C, et al. The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity. Aliment Pharmacol Ther. 2018;48:1260–1270

Article  CAS  PubMed  Google Scholar 

Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149:389–397

Article  PubMed  Google Scholar 

Hagstrom H, Nasr P, Ekstedt M, Hammar U, Stal P, Hultcrantz R, et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol. 2017;67:1265–1273

Article  PubMed  Google Scholar 

Vilar-Gomez E, Calzadilla-Bertot L, Wai-Sun Wong V, Castellanos M, Aller-de la Fuente R, Metwally M, et al. Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study. Gastroenterology. 2018;155:443–457

Article  PubMed  Google Scholar 

Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010;52:886–893

Article  CAS  PubMed  Google Scholar 

Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson I, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381:468–475

Article  CAS  PubMed  Google Scholar 

Wanless I, Nakashima E, Sherman M. Regression of human cirrhosis morphologic features and the genesis of incomplete septal cirrhosis. Arch Pathol Lab Med. 2000;124:1599–1607

Article  CAS  PubMed  Google Scholar 

Sun Y, Zhou J, Wang L, Wu X, Chen Y, Piao H, et al. New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment. Hepatology. 2017;66:1438–1450

Article  Google Scholar 

Wang B, Sun Y, Zhou J, Wu X, Chen S, Wu S, et al. Advanced septa size quantitation determines the evaluation of histological fibrosis outcome in chronic hepatitis B patients. Mod Pathol. 2018;31:1567–1577

Article  CAS  PubMed  Google Scholar 

Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149:367–378

Article  PubMed  Google Scholar 

Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease:practice guidance from the American association for the study of liver diseases. Hepatology. 2018;67:328–357

Article  PubMed  Google Scholar 

Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care. 2000;23:57–63

Article  CAS  PubMed  Google Scholar 

Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol. 2008;48:835–847

Article  PubMed  Google Scholar 

Newsome PN, Sasso M, Deeks JJ, Paredes A, Boursier J, Chan WK, et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol. 2020;5:362–373

Article  PubMed  PubMed Central  Google Scholar 

Noureddin M, Truong E, Gornbein JA, Saouaf R, Guindi M, Todo T, et al. MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis. J Hepatol. 2021;76:781–787

Article  PubMed  Google Scholar 

Sun Y, Zhou J, Wu X, Chen Y, Piao H, Lu L, et al. Quantitative assessment of liver fibrosis (qFibrosis) reveals precise outcomes in Ishak “stable” patients on anti-HBV therapy. Sci Rep. 2018;8:2989

Article  PubMed  PubMed Central  Google Scholar 

Theise ND, Jia J, Sun Y, Wee A, You H. Progression and regression of fibrosis in viral hepatitis in the treatment era: the Beijing classification. Mod Pathol. 2018;31:1191–1200

Article  PubMed  Google Scholar 

Kleiner DE, Makhlouf HR. Histology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in adults and children. Clin Liver Dis. 2016;20:293–312

Article  PubMed  Google Scholar 

Luo Y, Oseini A, Gagnon R, Charles ED, Sidik K, Vincent R, et al. An evaluation of the collagen fragments related to fibrogenesis and fibrolysis in nonalcoholic steatohepatitis. Sci Rep. 2018;8:12414

Article  PubMed  PubMed Central  Google Scholar 

Mak KM, Mei R. Basement membrane type IV collagen and laminin an overview of their biology and value. Anat Rec. 2017;300:1371–1390

Article  CAS  Google Scholar 

Wells RG. Cellular sources of extracellular matrix in hepatic fibrosis. Clin Liver Dis. 2008;12:759–768

Article  PubMed  PubMed Central  Google Scholar 

Honda Y, Yoneda M, Kobayashi T, Iwaki M, Kawamura N, Nogami A, et al. Meta-analysis of the diagnostic accuracy of serum type IV collagen 7S concentration for the staging of liver fibrosis in nonalcoholic fatty liver disease. Hepatol Res. 2023;53:219–227

Article  CAS  PubMed  Google Scholar 

Ishiba H, Sumida Y, Seko Y, Tanaka S, Yoneda M, Hyogo H, et al. Type IV collagen 7S is the most accurate test for identifying advanced fibrosis in NAFLD with type 2 diabetes. Hepatol Commun. 2021;5:559–572

Article  CAS  PubMed  Google Scholar 

Appunni S, Rubens M, Ramamoorthy V, Anand V, Khandelwal M, Sharma A. Biglycan: an emerging small leucine-rich proteoglycan (SLRP) marker and its clinicopathological significance. Mol Cell Biochem. 2021;476:3935–3950

Article  CAS  PubMed  Google Scholar 

Yu M, He X, Song X, Gao J, Pan J, Zhou T, et al. Biglycan promotes hepatic fibrosis through activating heat shock protein 47. Liver Int. 2022;43:500–512

Article  PubMed  Google Scholar 

Kozumi K, Kodama T, Murai H, Sakane S, Govaere O, Cockell S, et al. Transcriptomics identify thrombospondin-2 as a biomarker for NASH and advanced liver fibrosis. Hepatology. 2021;74:2452–2466

Article  CAS  PubMed  Google Scholar 

Chen W, Wu X, Yan X, Xu A, Yang A, You H. Multitranscriptome analyses reveal prioritized genes specifically associated with liver fibrosis progression independent of etiology. Am J Physiol Gastrointest Liver Physiol. 2019;316:G744–G754

Article  CAS  PubMed  Google Scholar 

Wang Q, You H, Ou X, Zhao X, Sun Y, Wang M, et al. Non-obese histologically confirmed NASH patients with abnormal liver biochemistry have more advanced fibrosis. Hep Int. 2019;13:766–776

Article  Google